|Articles|November 14, 2018
CSF-1 drops demonstrate efficacy, safety in clinical studies for treatment of presbyopia
Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.
Advertisement
Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision
2
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives
3
AAO 2025 Takeaways: How imaging and remote monitoring are transforming retinal care
4
Ocular Therapeutix randomizes first patient in HELIOS-3
5













































.png)


